Our results support previously reported studies which show that the combination of TGF-β and PD-L1 blockade increased the percentages of CD8+ T effector cells in the tumor bed [27] which correlates with the improved tumor eradication of the combination treatment. This evidence concerns the gene CD8A and neoplasm.